Different efficacy data for Chinese COVID-19 vaccine "real and valid"-media

"But these two results are both real and valid," Yang said, without offering further details for the data. CNBG did not participate in the analysis or review of clinical trial data released by regulators in countries where its vaccine was being trialed, Yang said.

Reuters | Beijing | Updated: 02-01-2021 09:20 IST | Created: 02-01-2021 09:20 IST
Different efficacy data for Chinese COVID-19 vaccine "real and valid"-media

Different efficacy results for a Chinese COVID-19 vaccine released separately in China and in United Arab Emirates are both real and valid, an executive at China National Biotec Group (CNBG) told state media. China approved its first COVID-19 vaccine for general public use on Thursday, a shot developed by an affiliate to state-backed Sinopharm, after the developer said the vaccine showed 79.34% efficacy based on an interim analysis of late-stage clinical trials.

That rate is lower than the 86% rate for the same vaccine reported by the United Arab Emirates on Dec. 9. Countries have certain differences in their standards and procedures in diagnosing patients, and the final results of COVID-19 case identification were different, Yang Xiaoming, chairman at Sinopharm unit's CNBG, told Global Times, a tabloid published by the People's Daily, the official newspaper of China's ruling Communist Party.

"Therefore, there were differences between the comprehensive multi-country data we reviewed and the protection rate data previously evaluated by the UAE and Bahrain," Global Times quoted Yang as saying in a report published on Thursday. "But these two results are both real and valid," Yang said, without offering further details for the data.

CNBG did not participate in the analysis or review of clinical trial data released by regulators in countries where its vaccine was being trialed, Yang said. The vaccine, developed by CNBG's unit Beijing Biological Products Institute, along with another candidate from a Wuhan-based unit of CNBG, are being tested in Phase III clinical trials outside China.

Trials for CNBG's candidates have recruited over 60,000 participants aged between 18-60, Yang said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Addressing conflict-related sexual violence at long last

... ...

Why unequal access to coronavirus vaccines is a threat to us all

... ...

India’s love affair with fossil fuels: the path to sustainable development?

... ...

Videos

Latest News

MP CM announces Rs 1 cr aid to kin of jawan killed in C'garh

Madhya Pradesh Chief Minister Shivraj Singh Chouhan has announced Rs one crore financial assistance to the family of a security personnel from the state, who was killed in Chhattisgarh two days back in a blast of IED planted by Naxals, offi...

Disneyland, other California theme parks, stadiums could reopen April 1

California health officials set new rules on Friday that would allow Disneyland and other theme parks, stadiums, and outdoor entertainment venues to reopen as early as April 1, after a closure of nearly a year due to the coronavirus pandemi...

Tennis-Argentine qualifier Francisco keeps alive hopes of 'Cerundolo sweep'

Francisco Cerundolo continued to fly the family flag high in his home country by reaching his maiden ATP Tour semi-final at the Argentina Open on Friday, a week after his teenaged brother Juan Manuel won the Cordoba Open title. Qualifier Ju...

69th Senior National Volleyball C'ship kickstarts in Bhubaneswar

The 69th Senior National Volleyball Championship has kick-started at the Biju Patnaik Indoor Stadium in KIIT Deemed to be University here in which for the first time, players from union territory Ladakh are participating in the championship...

Give Feedback